Analyst Price Targets — MDGL
Latest News for MDGL
CONSHOHOCKEN, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference on Thursday, Sept.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eighteen research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and fifteen have issued a buy rating on the
MASH cirrhosis could significantly expand Rezdiffra's addressable market. Madrigal's developing pipeline could reduce its dependence on Rezdiffra.
Allworth Financial LP bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 3,562 shares of the biopharmaceutical company's stock, valued at approximately $1,913,000. Several other hedge funds and other institutional investors
CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MDGL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.